{"url":"https://newsforagent.com/news/2026-11-21/concentrix-sbs-law-securities-investigation","markdown_url":"https://newsforagent.com/news/2026-11-21/concentrix-sbs-law-securities-investigation.md","title":"Concentrix Faces SBS Law Probe","headline":"SBS Law Investigates Concentrix Over Statements Tied to $1.05 Billion Goodwill Impairment","description":"Schall, Brown & Schwartz is investigating Concentrix for securities law violations after two 2026 revenue outlook cuts and a $1.05 billion noncash goodwill impairment.","section":"Legal & Disputes","published_at":"2026-11-21T23:30:31+00:00","modified_at":"2026-11-21T23:30:31+00:00","author":"News Desk","key_takeaways":["Schall, Brown & Schwartz LLP is investigating Concentrix for potential securities law violations.","Concentrix lowered its revenue and adjusted earnings forecasts on June 29, 2026, and cut its revenue outlook again on September 29, 2026.","The September 29, 2026 disclosure included a $1.05 billion noncash goodwill impairment.","Pomerantz LLP and Bronstein, Gewirtz & Grossman, LLC have also opened investigations into Concentrix."],"companies":[{"name":"Concentrix","is_primary":true,"profile_url":null,"website":"https://www.concentrix.com"}],"source":{"publisher":"Business Wire","title":"CNXC Investors Have Opportunity to Join Concentrix Corporation Fraud Investigation with SBS Law","url":"https://www.businesswire.com/news/home/20261121969940/en/"},"other_sources":[{"publisher":"The future of trading","url":"https://capital.com/en-int/news/amd-investors-have-opportunity-to-join-advanced-micro-devices-inc"},{"publisher":"FinancialContent Business Page","url":"https://www.financialcontent.com/article/bizwire-2026-11-21-npce-investors-have-opportunity-to-join-neuropace-inc-fraud-investigation-with-sbs-law"},{"publisher":"FinancialContent Business Page","url":"https://www.financialcontent.com/article/bizwire-2026-11-21-aadx-investors-have-opportunity-to-join-applied-aerospace-and-defense-inc-fraud-investigation-with-sbs-law"},{"publisher":"PR Newswire","url":"https://www.prnewswire.com/news-releases/charter-communications-investigation-initiated-kahn-swick--foti-llc-investigates-the-officers-and-directors-of-charter-communications-inc---chtr-302947396.html"},{"publisher":"PR Newswire","url":"https://www.prnewswire.com/news-releases/kyverna-therapeutics-investigation-initiated-kahn-swick--foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc---kytx-302947399.html"}],"tags":["Legal & Disputes","Concentrix"],"body_markdown":"Schall, Brown & Schwartz LLP is investigating Concentrix Corporation for potential violations of the securities laws, the firm said in a November 21, 2026 announcement. The [Business Wire](https://www.businesswire.com/news/home/20261121969940/en/) release states that the inquiry concerns whether Concentrix issued false or misleading statements or failed to disclose information pertinent to investors.\n\n## What SBS Law Is Examining at Concentrix\n\nConcentrix is a Nasdaq-listed company trading under the ticker CNXC. The investigation centers on two 2026 outlook cuts and the impairment charge that accompanied the second one.\n\nConcentrix reported its second-quarter financial results on June 29, 2026, lowering its revenue and adjusted earnings forecasts. The company then lowered its revenue outlook again on September 29, 2026, while also disclosing a noncash goodwill impairment of $1.05 billion.\n\nSBS Law is a national shareholder rights litigation firm. Its founding partners are Brian Schall, Andrew Brown and David Schwartz, and the firm said it represents investors in securities class actions and shareholder rights litigation. SBS invited shareholders to contact the firm to discuss their rights free of charge.\n\nThe same firm has opened other investigations recently. [The future of trading](https://capital.com/en-int/news/amd-investors-have-opportunity-to-join-advanced-micro-devices-inc) reported on November 20, 2026 that SBS Law announced an investigation into Advanced Micro Devices, citing a Hunterbrook report alleging AMD issued false statements and bills over 20% of revenue to China and Hong Kong.\n\n## Earlier Concentrix Probes by Other Firms\n\nPomerantz LLP is investigating Concentrix for potential securities fraud and advising investors to contact the firm, according to [FinancialContent Business Page](https://www.financialcontent.com/article/bizwire-2026-11-21-npce-investors-have-opportunity-to-join-neuropace-inc-fraud-investigation-with-sbs-law) alerts dated October 20, October 27, November 3 and November 10, 2026.\n\nBronstein, Gewirtz & Grossman, LLC is also investigating potential securities claims against Concentrix, The future of trading reported on October 27, 2026. That report noted Concentrix disclosed a $1.05 billion goodwill impairment in the third quarter of 2026, bringing total impairments to about $2.57 billion.\n\n## Other Securities Investigations Announced November 21\n\nSBS Law announced a similar investigation into NeuroPace, Inc. On November 21, 2026, following third-quarter 2026 results showing a year-over-year revenue decline and a 37.1% share drop, [FinancialContent Business Page](https://www.financialcontent.com/article/bizwire-2026-11-21-aadx-investors-have-opportunity-to-join-applied-aerospace-and-defense-inc-fraud-investigation-with-sbs-law) reported. The same outlet reported an SBS Law investigation into Applied Aerospace & Defense, Inc. Concerning statements about supply constraints and Apache helicopter rotor head overhaul approvals.\n\nKahn Swick & Foti, LLC announced investigations into Charter Communications, Inc. And Kyverna Therapeutics, Inc. On November 21, 2026, [PR Newswire](https://www.prnewswire.com/news-releases/charter-communications-investigation-initiated-kahn-swick--foti-llc-investigates-the-officers-and-directors-of-charter-communications-inc---chtr-302947396.html) reported. The Charter inquiry cites second-quarter 2025 EBITDA of $5.7 billion, which missed consensus by 2.4% excluding a $45 million one-time benefit, and a loss of 117,000 Internet customers. The Kyverna inquiry follows a securities lawsuit alleging the IPO prospectus misstated or omitted material facts about its lead product candidate KYV-101.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}